As nicotine pouches continue to emerge within tobacco harm reduction discussions, policymakers are increasingly faced with a fundamental question: how should the health risks of these products be assessed?
Public debate often reduces the issue to a simple question of whether nicotine pouches are “safe” or “unsafe.” While understandable, this framing overlooks how modern toxicology evaluates risk. Increasingly, researchers examine not only whether products contain nicotine, but also the extent to which users are exposed to the harmful chemicals responsible for smoking-related disease. Understanding exposure has become central to evaluating the potential public health impact of smoke-free nicotine products, and this is where biomarker science has assumed growing importance.
Biomarkers cannot predict every long-term health outcome, nor do they determine whether a product is risk-free. However, they provide one of the most objective methods available for measuring how much of a harmful substance actually enters the body. As governments review the regulation of emerging nicotine products, biomarker evidence is becoming an increasingly important component of evidence-based policymaking.
Understanding Biomarkers
In tobacco and nicotine research, biomarkers are measurable biological indicators that reflect exposure to specific chemicals or physiological responses within the body. They are commonly measured through blood, urine, saliva, or breath samples and allow researchers to quantify exposure to harmful and potentially harmful constituents associated with tobacco use.
This represents an important shift in scientific evaluation. Rather than relying solely on laboratory analysis of product ingredients, biomarker studies assess what users are actually exposed to under real-world conditions. They therefore provide a more direct indication of the biological consequences of using different nicotine products.
For products such as nicotine pouches, this distinction is particularly relevant. While nicotine remains the primary active ingredient, the absence of tobacco combustion means users are generally not exposed to the thousands of combustion-related chemicals generated by cigarette smoke. Biomarker studies help determine whether this difference in product design results in meaningful differences in human exposure.
Why Exposure Matters
The overwhelming burden of smoking-related disease is not caused by nicotine alone. It is primarily associated with repeated exposure to toxicants produced during combustion, including tobacco-specific nitrosamines, volatile organic compounds, polycyclic aromatic hydrocarbons, carbon monoxide, heavy metals, and numerous other harmful constituents found in cigarette smoke.
Because nicotine pouches contain no tobacco leaf and involve no combustion, researchers have increasingly examined whether users experience substantially lower exposure to these toxic substances compared with smokers.
Biomarker research addresses precisely this question.
Instead of asking whether nicotine pouches contain nicotine—which they clearly do—it asks whether individuals who use them absorb the same harmful chemicals associated with smoking-related disease.
This distinction is central to understanding the scientific basis of tobacco harm reduction.
What the Evidence Shows
An expanding body of biomarker research suggests that adult smokers who completely switch from combustible cigarettes to tobacco-free nicotine pouches experience substantial reductions in exposure to many of the harmful constituents most strongly associated with smoking.
Studies have consistently reported reductions in biomarkers of tobacco-specific nitrosamines, volatile organic compounds, and other combustion-related toxicants following complete switching. These findings align with what would be expected from products that eliminate combustion and tobacco smoke.
Importantly, biomarker studies do not demonstrate that nicotine pouches are harmless. Nicotine remains an addictive substance, and researchers continue to investigate other potential health effects associated with long-term use, including local oral changes and cardiovascular outcomes.
Nevertheless, reductions in exposure remain scientifically significant because they indicate that users are absorbing considerably fewer of the toxic chemicals responsible for much of smoking-related disease.
Exposure and Risk Are Not Identical
One of the most important principles in toxicology is that exposure should not be confused with risk.
Lower exposure to harmful chemicals does not automatically mean that a product is safe, nor does it guarantee reductions in long-term disease. Chronic illnesses such as cardiovascular disease, chronic obstructive pulmonary disease, and many cancers develop over decades. Demonstrating changes in disease incidence therefore requires long-term epidemiological studies that extend far beyond the timeframes currently available for nicotine pouches.
At the same time, it would also be inappropriate to ignore biomarker evidence simply because long-term outcome data are still emerging.
Scientific assessment does not rely upon a single study or one type of evidence. Rather, regulators typically consider product chemistry, toxicological testing, biomarker research, clinical investigations, behavioural studies, and population-level evidence together. Biomarkers therefore represent an important bridge between laboratory science and long-term epidemiology, helping researchers understand whether changes in exposure are occurring while longer-term studies continue.
What This Means for Regulation
The growing body of biomarker evidence reinforces an important principle for regulators: products that expose users to substantially different levels of harmful constituents should be evaluated according to their own characteristics rather than automatically being treated as equivalent.
This does not imply deregulation or diminished public health protections.
Nicotine pouches should continue to be subject to robust manufacturing standards, ingredient transparency, age restrictions, responsible marketing requirements, post-market surveillance, and ongoing scientific evaluation. Strong youth protections remain essential, as does continued monitoring of long-term health outcomes.
However, evidence-based regulation should also recognise that products occupying different positions along the exposure continuum may warrant different regulatory approaches. Treating products with fundamentally different toxicological profiles as though they are identical risks overlooking one of the central findings emerging from contemporary nicotine research.
Looking Ahead
Biomarker science has become one of the most valuable tools available for understanding modern nicotine products. While it cannot answer every question about long-term health outcomes, it provides objective evidence regarding the chemicals users are actually exposed to and how those exposures compare with combustible cigarette smoking.
Current evidence increasingly indicates that tobacco-free nicotine pouches substantially reduce exposure to many harmful combustion-related toxicants compared with continued smoking. At the same time, nicotine pouches are not risk-free, and important questions regarding their long-term health effects remain the subject of ongoing investigation.
For policymakers, the implication is clear. Decisions about nicotine regulation should not be based solely on whether products contain nicotine. They should also consider what users are exposed to, how those exposures compare across product categories, and how the totality of scientific evidence can support proportionate, evidence-based regulation.
As research continues to evolve, biomarker studies will remain an essential component of understanding where nicotine pouches fit within the broader continuum of tobacco harm reduction and how future regulatory frameworks can best balance public health protection with scientific evidence.
